• Cell Source presented at the LD Micro Invitational Conference in Los Angeles this week.
• It outlined plans to expand clinical programs in mismatched donor stem cell and kidney transplants, develop off-the-shelf CAR-T therapy, and pursue a Nasdaq uplisting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cell Source Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.